OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round.

Richard Silverman, PhD, is a Northwestern University chemist whose name bears the building. His experimentation led to the ...

Drug discovery has long relied on two key strategies: target-based and phenotypic screening. Recombinant technologies and genomics opened the door to modern target-based drug discovery (TBDD), ...

Nearly 1 in 7 adults in the United States lives with chronic kidney disease, a condition that often advances quietly until ...

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...